top of page
O nás: Who We Are
mMEDCON logo (1).png

Do you know that....
Approximately 1 in 40 people are carriers of the genetic mutation that causes SMA, making it one of the most common genetic disorders.

In the MENA region, the lack of standardized referral pathways for Duchenne Muscular Dystrophy (DMD) causes delays in diagnosis and treatment. We aim to build AI-driven software to analyze low MRI muscle tissue scan to provide early detection and comprehensive evaluation of disease management.

Key Features of M^3:

AI Integration - Utilizes Residual U-net and AUTOMAP for enhanced image reconstruction and diagnostic accuracy.
Cost-Effective - Offers affordable low-field MRI imaging, reducing healthcare costs.
Accessible - portable low-field MRI devices for decentralized diagnostics.

Screenshot 2024-07-09 134341.png

Do you know that....
DMD patients usually lose the ability to walk by age 12 and often die of respiratory failure or cardiac insufficiency around age 20


High Prevalence and Genetic Factors

Spinal Muscular Atrophy (SMA) is significantly more prevalent in the Gulf Cooperation Council (GCC) populations, with rates at least 50 times higher than in the US due to genetic factors like consanguinity. Duchenne Muscular Dystrophy (DMD), caused by a mutation on the X chromosome, primarily affects male children and leads to progressive muscle degeneration.


Challenges in Diagnosis and Progression

DMD is characterized by progressive muscle weakness, beginning in the pelvic girdle and extending to distal extremities. Traditional diagnostic methods like muscle biopsies are limited in scope. It is also invasive and often painful, requiring recovery time. Muscle MRI offers a non-invasive alternative, providing high-resolution images and comprehensive evaluations of multiple muscles, identifying early muscle changes and aiding in disease progression monitoring.


Importance of Early Diagnosis and Advanced Tools

The severe complications of DMD, including cardiac and respiratory issues, underscore the importance of early diagnosis and treatment to slow disease progression.

Therefore, there is a critical need for innovative, non-invasive diagnostic tools and comprehensive care plans to address these challenges. Our project aims to fill this gap by providing state-of-the-art diagnostic solutions and personalized care strategies.

Mission &

AI powered muscle analytics

simple to use for clinicians

easy access for patients

early and reliable diagnosis

A clean, minimalist icon featuring a com

Aim and objectives

  1. Develop novel, accessible methods for early and accurate diagnosis of musculoskeletal disorders.

  2. Create effective therapies to manage disease progression and improve patient outcomes.

  3. Design personalized care plans that cater to individual patient needs.

  4. Integrate supportive technologies to enhance daily living activities and provide emotional support.

  5. Promote education and awareness of genetic conditions and the importance of early diagnosis.



+421 902 950 910



  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
bottom of page